GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Action(s) initiated or orders passed

Regulatory & Legal View source PDF Explain this filing

GLAXO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.3%Reaction day

₹2600.20

prior close

₹2655.00

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.2%+1.5% vs market

Pharmaceuticals peers, median of 155sector-0.2%+1.5% vs sector

On the reaction day the stock moved 1.5 pts more than Nifty Midcap 150 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.3

15m

+0.2

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.3-0.2+1.5-0.2+1.5

Next day

+0.7-0.4+1.1-0.9+1.6

+1.9+0.2+1.7-0.7+2.6

+1.3+0.8+0.5-0.4+1.7

-1.2-0.3-0.8-1.7+0.5

-2.6-2.0-0.6-3.4+0.8

-4.7-2.7-2.0-3.0-1.7

15d

-6.8-7.1+0.2-5.3-1.5

-12.3-11.3-1.0-8.5-3.8

-4.2+0.8-5.0+3.3-7.5

-11.5+3.5-15.1+7.5-19.0

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

GlaxoSmithKline Pharmaceuticals has received an order dated 21st January 2026 from the Deputy Commissioner of CGST & Central Excise, Indore, disallowing certain GST input tax credits claimed in Madhya Pradesh. The total demand is Rs. 3.79 crore, comprising Rs. 1.90 crore in tax and an equal amount in penalty, with interest yet to be quantified. The demand covers FY 2019-20 through FY 2022-23. The company says there is no material impact on its financial operations and is evaluating the order to decide on further action, which may include appeal.

Likely market impact

The demand amount of Rs. 3.79 crore is small relative to GSK Pharma's overall scale and is unlikely to move the stock. The disclosure is a procedural compliance item, and the final outcome will depend on the company's response and any appeal filed.